企業概要
Sol-Gel Technologies Ltd. is a healthcare entity dedicated to the development of topical dermatological medications designed to treat severe skin conditions across international markets including Israel, China, Switzerland, Canada, and the United States. The company operates within the broader healthcare sector, specifically functioning as a biotechnology firm focused on innovative drug delivery systems such as its non-antibiotic topical product, Twyneo. This specialized biotechnology operation employs a workforce of 28 individuals and maintains a total market capitalization of $241.77 million. With annual revenue reaching $19.39 million, the company's valuation metrics suggest a market capitalization that significantly exceeds its current revenue base, indicating a high premium assigned by investors to its growth potential and proprietary technology pipeline within the competitive biotechnology landscape.
財務健全性
The company reported revenue of $19.39 million for the trailing twelve months, yet this revenue generated a net income loss of $6.127 million and an EBITDA of -$7.483 million, revealing a cost structure where expenses substantially outweigh gross revenues before interest and taxes. Despite the negative net income, the company generated positive free cash flow of $617,000, which provides a degree of financial flexibility by allowing the firm to fund operations and potentially invest in research without relying solely on external financing. The margins reflect the challenges typical of early-stage biotechnology development, with a gross margin of -17.6%, an operating margin of -497.8%, and a profit margin of -31.6%, all of which indicate significant operational losses relative to sales. The balance sheet shows a cash position of $24.00 million against total debt of $991,000, resulting in a debt-to-equity ratio of 4.34, which suggests a leveraged capital structure heavily weighted toward equity financing rather than traditional debt obligations. Liquidity is supported by a current ratio of 4.37, indicating that the company possesses 4.37 times the current assets necessary to cover its short-term liabilities. However, the return on equity stands at -23.7% and the return on assets is -14.4%, metrics that demonstrate that management has not yet achieved profitability and is currently destroying shareholder value on a percentage basis relative to the capital deployed.
バリュエーション評価
Valuation metrics for Sol-Gel Technologies Ltd. are constrained by its lack of earnings, as evidenced by a trailing P/E ratio that is not applicable and a forward P/E of -10.94, implying that the market anticipates negative earnings to persist or that traditional multiple analysis is not yet suitable. The price-to-book ratio stands at 9.10, suggesting that the market values the company at a premium of more than nine times its tangible book value, reflecting high expectations for future asset appreciation or intangible value. Alternative valuation measures such as a price-to-sales ratio of 12.47 and an EV/EBITDA of -24.90 further highlight the disconnect between current operational performance and market pricing, relying entirely on revenue generation rather than profitability for valuation support. The stock price has exhibited significant volatility, trading between a 52-week low of $4.02 and a high of $97.97, meaning the current price sits well below the 52-week peak but remains far above the recent lows. The stock carries a beta of 1.27, indicating that its price volatility is 27% higher than the broader market, which is consistent with the high-risk profile of small-cap biotechnology companies.
Growth & Income
Revenue growth for the trailing twelve months is substantial at 150.4% year-over-year, while earnings growth is not applicable due to the company's negative net income, implying that revenue expansion is occurring without a corresponding improvement in profitability. The company does not distribute dividends to shareholders, as indicated by a dividend yield of not applicable and a payout ratio of 0.0%, meaning all earnings are theoretically available for reinvestment or are absorbed by losses. Since the company is a non-dividend payer, it follows a strategy of reinvesting resources into its dermatological drug development and operational scaling rather than returning capital to investors. The overall profile characterizes Sol-Gel as a high-revenue-growth, non-income-generating biotechnology firm that relies on external capital or cash reserves to fund its expansion until it can generate sustainable net income.